In the Claims:

1. (currently amended) ~~Transdermal~~ A transdermal pharmaceutical preparation for the treatment of Parkinson's disease containing a combination of at least two active substances, ~~characterised in that~~ wherein said pharmaceutical preparation contains a combination selected from the group consisting of:

[[-]] a combination of a dopamine agonist and an anti-cholinergically active substance[[, or]] ;

[[-]] a combination of L-dopa and an anticholinergically active substance[[, or]] ;

[[-]] a combination of a dopamine agonist and an NMDA receptor antagonist[[, or]] ; and

[[-]] a combination of L-dopa and an NMDA receptor antagonist.

2. (currently amended) ~~Pharmaceutical~~ The pharmaceutical preparation according to claim 1, ~~characterised in that it~~ wherein said pharmaceutical preparation contains a combination of three active substances~~, namely:~~ selected from the group consisting of:

[[-]] a combination of a dopamine agonist or L-dopa, an anticholinergically active substance, and an NMDA receptor antagonist[[; or]] and

[[-]] a combination of a dopamine agonist or L-dopa, an anticholinergically active substance, and a monoamine oxidase B inhibitor.

3. (currently amended) ~~Pharmaceutical~~ The pharmaceutical preparation according to claim 1, wherein ~~or 2, characterised in that~~ the group of dopamine agonists ~~comprises~~ is selected from the group consisting of lisuride, bromocriptine, pramipexol, ropinirole, rotigotine, terguride, carbergoline, apomorphine, piribedile, pergolide and 4-propyl-9-hydroxynaphthoxazine (PHNO).

4. (currently amended) ~~Pharmaceutical~~ The pharmaceutical preparation according to claim 2, wherein ~~or 3, characterised in that~~ the group of monoamine oxidase inhibitors ~~consists of~~ comprises monoamine oxidase B-selective inhibitors~~, with selegiline being particularly preferred~~.

5. (currently amended) ~~Pharmaceutical~~ The pharmaceutical preparation according to ~~claims~~ claim 1, wherein ~~to 4, characterised in that~~ the group of anticholinergics comprises an ~~the following~~ active ~~substances:~~ substance selected from the group consisting of bipreriden, trihexyphenidyl, procyclidine, bornaprine, metixene, orphenadrine, scopolamine, atropine and other belladonna alkaloids, benzatropine and nicotine.

6. (currently amended) ~~Pharmaceutical~~ The pharmaceutical preparation according to

claim 1, wherein ~~any one of the preceding claims, characterised in that~~ the group of the NMDA receptor antagonists comprises memantine and amantadine.

7. (currently amended) ~~Pharmaceutical~~ The pharmaceutical preparation according to claim 1, wherein said pharmaceutical preparation further ~~any one of the preceding claims, characterised in that it additionally~~ contains an active substance selected from the group of the sympathomimetics.

8. (currently amended) ~~Pharmaceutical~~ The pharmaceutical preparation according to claim 7, wherein ~~characterised in that~~ the group of sympathomimetics comprises an active ~~substances~~ substance selected from the group consisting of the phenylethylamine derivatives~~, 3,4-methylenedioxymethamphetamine being particularly preferred~~.

9. (currently amended) ~~Pharmaceutical~~ The pharmaceutical preparation according to claim 1, wherein ~~any one of the preceding claims, characterised in that~~ said pharmaceutical preparation additionally contains at least one further active substance selected from the group ~~comprising~~ consisting of catechol-O-methyl transferase inhibitors and decarboxylase inhibitors~~, with entacapone, benserazide and carbidopa being particularly preferred~~.

10. (currently amended) ~~Pharmaceutical~~ The pharmaceutical preparation according to claim 1, wherein ~~any one of the preceding claims, characterised in that~~ said pharmaceutical preparation additionally contains at least one active substance selected from the group consisting of the beta blockers~~, preferably from the group comprising propranolol, timolol, pindolol and atenolol~~.

11. (canceled)

12. (currently amended) ~~Pharmaceutical~~ The pharmaceutical preparation according to claim 1, wherein ~~any one of the preceding claims, characterised in that~~ said pharmaceutical preparation is ~~present as~~ a transdermal therapeutic system~~, preferably~~ in the form of an active substance patch adhering to the skin.

13. (currently amended) ~~Pharmaceutical~~ The pharmaceutical preparation according to claim 12, wherein ~~characterised in that the~~ said transdermal therapeutic system comprises ~~at least two active substances are contained in~~ different layers or compartments ~~of the transdermal therapeutic system~~ for containing said at least two active substances.

14. (new) The pharmaceutical preparation according to claim 4, wherein said monoamine oxidase B-selective inhibitors are selegiline.

15. (new) The pharmaceutical preparation according to claim 8, wherein said phenylethylamine derivatives are, 3,4-methylenedioxymethamphetamine.

16. (new) The pharmaceutical preparation according to claim 9, wherein said at least one further active substance is selected from the group consisting of entacapone, benserazide and carbidopa.

17. (new) The pharmaceutical preparation according to claim 10, wherein said beta blockers are selected from the group consisting of propranolol, timolol, pindolol and atenolol.

18. (new) A transdermal pharmaceutical preparation for the treatment of Parkinson's disease, wherein said pharmaceutical preparation contains selegiline and rotigotine.